Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$130.93 USD

130.93
5,169,822

+0.24 (0.18%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $130.94 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ABT) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis

Mark Vickery headshot

Top Research Reports for Abbott, Netflix & Philip Morris

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Netflix (NFLX) and Philip Morris (PM).

Zacks Equity Research

Company News for Jul 18, 2019

by Zacks Equity Research

Companies In The News Are: ABT, USB, ERIC, TXT

Trina Mukherjee headshot

IVD Market Sustains Momentum: 3 Stocks in Focus

by Trina Mukherjee

In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.

Zacks Equity Research

Abbott (ABT) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Abbott (ABT) Tops Q2 Earnings Estimates, Lifts EPS Guidance

by Zacks Equity Research

Abbott (ABT) registers strong Cardiovascular and Neuromodulation sales on double-digit growth in Electrophysiology, Heart Failure and Structural Heart.

Zacks Equity Research

Mixed Housing Data for June

by Zacks Equity Research

Mixed Housing Data for June

Mark Vickery headshot

Housing Starts, Building Permits Mixed; Q2 for BAC, USB, ABT

by Mark Vickery

Housing Starts were up slightly for June, but Building Permits disappointed.

Zacks Equity Research

Abbott (ABT) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 2.50% and -0.10%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Sreyoshi Mukherjee headshot

US-India Trade Tensions Rise: 3 Stocks in the Line of Fire

by Sreyoshi Mukherjee

As India moves toward self-sufficiency, U.S. MedTech bigwigs fret over possible losses.

Tracey Ryniec headshot

5 Stocks with Spectacular Earnings Charts

by Tracey Ryniec

These companies aren't just beating on earnings, their stocks are also on fire, hitting new 5-year highs.

Zacks Equity Research

Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand

by Zacks Equity Research

The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.

Zacks Equity Research

Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?

by Zacks Equity Research

Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.

Zacks Equity Research

ABT or BIO: Which Stock Has Better Potential Right Now?

by Zacks Equity Research

Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.

Kevin Cook headshot

Bull of the Day: Penumbra (PEN)

by Kevin Cook

This $6 billion innovator removes blood clots and the deadly shadow of stroke with catheter-based aspiration technologies

Zacks Equity Research

Abbott (ABT) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $83.69, moving +0.88% from the previous trading session.

Zacks Equity Research

Abbvie Decides to Acquire Allergan

by Zacks Equity Research

Abbvie Decides to Acquire Allergan

Mark Vickery headshot

AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20

by Mark Vickery

AbbVie (ABBV) has agreed to purchase Botox maker Allergan (AGN) for roughly $63 billion in cash and stock.

Zacks Equity Research

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed at $83.42 in the latest trading session, marking a +1.67% move from the prior day.

Zacks Equity Research

Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Abbott (ABT) gains from expansion of product portfolio and several regulatory clearances.

Zacks Equity Research

Abbott (ABT) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $81.24, marking a +0.62% move from the previous day.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life